TY - JOUR
T1 - Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists
AU - Carroll, CB
AU - Fackrell, R
AU - Grosset, D
AU - Mohamed, B
AU - Reddy, P
AU - Parry, M
AU - Chaudhuri, K
AU - Foltynie, T
PY - 2018/7/5
Y1 - 2018/7/5
N2 - In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.
AB - In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1138/viewcontent/fackrell_et_al_2018_noninvasive_options_for_wearing_off_in_parkinson_s_disease_a_clinical_consensus_from_a_panel_of_uk.pdf
M3 - Article
SN - 1758-2024
VL - 0
JO - Neurodegenerative Disease Management
JF - Neurodegenerative Disease Management
IS - 0
ER -